- Home
- BEEM vs ACRV Comparison
BEEM vs ACRV Comparison
Compare BEEM & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEM
- ACRV
- Stock Information
- Founded
- BEEM 2006
- ACRV 2018
- Country
- BEEM United States
- ACRV United States
- Employees
- BEEM N/A
- ACRV N/A
- Industry
- BEEM Semiconductors
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- BEEM Technology
- ACRV Health Care
- Exchange
- BEEM Nasdaq
- ACRV Nasdaq
- Market Cap
- BEEM 48.4M
- ACRV 47.8M
- IPO Year
- BEEM N/A
- ACRV 2022
- Fundamental
- Price
- BEEM $2.98
- ACRV $1.91
- Analyst Decision
- BEEM Strong Buy
- ACRV Buy
- Analyst Count
- BEEM 4
- ACRV 6
- Target Price
- BEEM $5.33
- ACRV $17.75
- AVG Volume (30 Days)
- BEEM 2.0M
- ACRV 3.3M
- Earning Date
- BEEM 11-13-2025
- ACRV 11-12-2025
- Dividend Yield
- BEEM N/A
- ACRV N/A
- EPS Growth
- BEEM N/A
- ACRV N/A
- EPS
- BEEM N/A
- ACRV N/A
- Revenue
- BEEM $33,362,000.00
- ACRV N/A
- Revenue This Year
- BEEM N/A
- ACRV N/A
- Revenue Next Year
- BEEM $45.38
- ACRV $805.34
- P/E Ratio
- BEEM N/A
- ACRV N/A
- Revenue Growth
- BEEM N/A
- ACRV N/A
- 52 Week Low
- BEEM $1.33
- ACRV $1.05
- 52 Week High
- BEEM $5.31
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- BEEM 59.19
- ACRV 70.94
- Support Level
- BEEM $2.82
- ACRV $1.77
- Resistance Level
- BEEM $2.96
- ACRV $1.84
- Average True Range (ATR)
- BEEM 0.24
- ACRV 0.12
- MACD
- BEEM 0.02
- ACRV 0.02
- Stochastic Oscillator
- BEEM 71.08
- ACRV 86.27
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.